mexiletine has been researched along with Torsade de Pointes in 13 studies
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a 28-year-old female patient with congenital type 2 long QT syndrome (LQTS) in which mexiletine shortened corrected QT interval (QTc) and effectively prevented refractory Torsade de Pointes (TdP) and ventricular fibrillation (VF)." | 8.12 | Mexiletine effectively prevented refractory Torsades de Pointes and ventricular fibrillation in a patient with congenital type 2 long QT syndrome. ( Kai, K; Nakashima, R; Sakamoto, K; Takase, S; Tsutsui, H, 2022) |
| "Erythromycin is a selective IKr-blocking, action potential duration (APD)-prolonging drug, which may induce early afterdepolarizations (EADs) and torsade de pointes ventricular tachycardia." | 7.70 | Suppression of erythromycin-induced early afterdepolarizations and torsade de pointes ventricular tachycardia by mexiletine. ( Fazekas, T; Krassói, I; Lengyel, C; Papp, JG; Varró, A, 1998) |
| "The arrhythmogenic and electrophysiologic properties of sotalol, a class III antiarrhythmic drug, administered alone and in combination with mexiletine, a class I antiarrhythmic drug, were compared in conscious dogs predisposed to torsade de pointes arrhythmias." | 7.69 | Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. ( Chézalviel-Guilbert, F; Davy, JM; Poirier, JM; Weissenburger, J, 1995) |
| "We report a 28-year-old female patient with congenital type 2 long QT syndrome (LQTS) in which mexiletine shortened corrected QT interval (QTc) and effectively prevented refractory Torsade de Pointes (TdP) and ventricular fibrillation (VF)." | 4.12 | Mexiletine effectively prevented refractory Torsades de Pointes and ventricular fibrillation in a patient with congenital type 2 long QT syndrome. ( Kai, K; Nakashima, R; Sakamoto, K; Takase, S; Tsutsui, H, 2022) |
| "It has been suggested that both pacing and treatment with mexiletine may reduce torsade de pointes (TdP) arrhythmias in patients with long QT syndrome 3 (LQT3), but it is not fully understood how these interventions could prevent TdP." | 3.72 | Effect of pacing and mexiletine on dispersion of repolarisation and arrhythmias in DeltaKPQ SCN5A (long QT3) mice. ( Breithardt, G; Carmeliet, E; Carmeliet, P; Fabritz, L; Franz, MR; Haverkamp, W; Kirchhof, P; Nuyens, D; Ottenhof, A; Rossenbacker, T, 2003) |
| "Erythromycin is a selective IKr-blocking, action potential duration (APD)-prolonging drug, which may induce early afterdepolarizations (EADs) and torsade de pointes ventricular tachycardia." | 3.70 | Suppression of erythromycin-induced early afterdepolarizations and torsade de pointes ventricular tachycardia by mexiletine. ( Fazekas, T; Krassói, I; Lengyel, C; Papp, JG; Varró, A, 1998) |
| "The arrhythmogenic and electrophysiologic properties of sotalol, a class III antiarrhythmic drug, administered alone and in combination with mexiletine, a class I antiarrhythmic drug, were compared in conscious dogs predisposed to torsade de pointes arrhythmias." | 3.69 | Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. ( Chézalviel-Guilbert, F; Davy, JM; Poirier, JM; Weissenburger, J, 1995) |
| "d-Sotalol was used to mimic LQT2, whereas ATX-II mimicked LQT3." | 1.30 | Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome. ( Antzelevitch, C; Shimizu, W, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Mirams, GR | 1 |
| Cui, Y | 1 |
| Sher, A | 1 |
| Fink, M | 1 |
| Cooper, J | 1 |
| Heath, BM | 1 |
| McMahon, NC | 1 |
| Gavaghan, DJ | 1 |
| Noble, D | 1 |
| Nakashima, R | 1 |
| Takase, S | 1 |
| Kai, K | 1 |
| Sakamoto, K | 1 |
| Tsutsui, H | 1 |
| Vicente, J | 1 |
| Johannesen, L | 1 |
| Hosseini, M | 1 |
| Mason, JW | 1 |
| Sager, PT | 1 |
| Pueyo, E | 1 |
| Strauss, DG | 1 |
| Aziz, PF | 1 |
| Tanel, RE | 1 |
| Zelster, IJ | 1 |
| Pass, RH | 1 |
| Wieand, TS | 1 |
| Vetter, VL | 1 |
| Vogel, RL | 1 |
| Shah, MJ | 1 |
| Sato, A | 1 |
| Chinushi, M | 1 |
| Suzuki, H | 1 |
| Numano, F | 1 |
| Hanyu, T | 1 |
| Iijima, K | 1 |
| Watanabe, H | 1 |
| Furushima, H | 1 |
| Fabritz, L | 1 |
| Kirchhof, P | 1 |
| Franz, MR | 1 |
| Nuyens, D | 1 |
| Rossenbacker, T | 1 |
| Ottenhof, A | 1 |
| Haverkamp, W | 2 |
| Breithardt, G | 1 |
| Carmeliet, E | 1 |
| Carmeliet, P | 1 |
| Takeuchi, T | 1 |
| Sato, N | 1 |
| Kawamura, Y | 1 |
| Takahashi, F | 1 |
| Sato, M | 1 |
| Kikuchi, K | 1 |
| Akasaka, N | 1 |
| Go, K | 1 |
| Fujimoto, K | 1 |
| Hasebe, N | 1 |
| Kehl, HG | 1 |
| Rellensmann, G | 1 |
| Yelbuz, TM | 1 |
| Krasemann, T | 1 |
| Vogt, J | 1 |
| Schulze-Bahr, E | 1 |
| Divekar, A | 1 |
| Soni, R | 1 |
| Chézalviel-Guilbert, F | 1 |
| Davy, JM | 1 |
| Poirier, JM | 1 |
| Weissenburger, J | 1 |
| Shimizu, W | 2 |
| Antzelevitch, C | 2 |
| Fazekas, T | 1 |
| Krassói, I | 1 |
| Lengyel, C | 1 |
| Varró, A | 1 |
| Papp, JG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Randomized, Placebo-Controlled Single-Dose, Five Period Crossover Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects[NCT01873950] | Phase 1 | 22 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Five Period Crossover Study of the Ability of Late Sodium or Calcium Current Block (Mexiletine, Lidocaine, or Diltiazem) to Balance the Electrocardiographic Effects of hERG Potassium Current Block (Dofetilide or Moxifloxacin)[NCT02308748] | Phase 1 | 22 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Different post-dose time-points employ different techniques for altering heart rate (leg raises and postural maneuvers). Using the measurements from all the time-points of postural maneuvers, the QT/RR relationship was modeled as a linear relationship between the square root of RR in seconds and QT in seconds and computed on a by subject, treatment and time-point basis. The change in the QT and heart rate relationship was assessed as the difference (mean and 95% CI) between the slopes from the models for each drug vs. placebo. (NCT01873950)
Timeframe: 24 hours
| Intervention | ratio (Mean) |
|---|---|
| Ranolazine 1500mg | 0.01 |
| Dofetilide 500mcg | 0.06 |
| Verapamil HCl 120 mg | 0.02 |
| Quinidine Sulfate 400mg | 0.11 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in spatial QRS-T angle for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | degrees per ng/ml (Mean) |
|---|---|
| Dofetilide 500mcg | -3.9 |
| Verapamil HCl 120 mg | 0.4 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in spatial QRS-T angle for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | degrees per mcg/ml (Mean) |
|---|---|
| Ranolazine 1500mg | -1.0 |
| Quinidine Sulfate 400mg | 2.7 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in ventricular gradient for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | mV.ns per ng/ml (Mean) |
|---|---|
| Dofetilide 500mcg | 4.0 |
| Verapamil HCl 120 mg | 1.2 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in ventricular gradient for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | mV.ns per mcg/ml (Mean) |
|---|---|
| Ranolazine 1500mg | -0.7 |
| Quinidine Sulfate 400mg | 1.6 |
Compute maximum mean placebo, and baseline-adjusted change for: spatial QRS-T angle (degrees) (NCT01873950)
Timeframe: 24 hours
| Intervention | degrees (Least Squares Mean) |
|---|---|
| Ranolazine 1500mg | -2.2 |
| Dofetilide 500mcg | -4.9 |
| Verapamil HCl 120 mg | -2.4 |
| Quinidine Sulfate 400mg | 3.9 |
Compute maximum mean placebo, and baseline-adjusted change for: ventricular gradient (mV*ms). (NCT01873950)
Timeframe: 24 hours
| Intervention | mV*ms (Least Squares Mean) |
|---|---|
| Ranolazine 1500mg | 2.5 |
| Dofetilide 500mcg | 4.8 |
| Verapamil HCl 120 mg | 4.2 |
| Quinidine Sulfate 400mg | 6.0 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in QTc for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | ms per ng/ml (Mean) | ||||
|---|---|---|---|---|---|
| Change in PR | Change in QTc | Change in QRS | Change in J-Tpeakc | Change in Tpeak-Tend | |
| Dofetilide 500mcg | -0.5 | 73.6 | 0.2 | 39.1 | 34.4 |
| Verapamil HCl 120 mg | 28.7 | 3.9 | 0.3 | -0.7 | 3.6 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in QTc for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | ms per mcg/ml (Mean) | ||||
|---|---|---|---|---|---|
| Change in PR | Change in QTc | Change in QRS | Change in J-Tpeakc | Change in Tpeak-Tend | |
| Quinidine Sulfate 400mg | 3.0 | 78.9 | 0.4 | 26.1 | 51.2 |
| Ranolazine 1500mg | 4.2 | 12.0 | 0.8 | 0.7 | 10.0 |
Compute maximum mean placebo, and baseline-adjusted change for: PR (ms), QRS (ms), J-Tpeak (ms), Tpeak-Tend (ms) and QTc (ms) (NCT01873950)
Timeframe: 24 hours
| Intervention | ms (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Change in PR interval | Change in QRS duration | Change in J-Tpeakc | Change in Tpeak-Tend | Change in QTc | |
| Dofetilide 500mcg | 2.3 | 1.1 | 39.5 | 40.0 | 79.3 |
| Quinidine Sulfate 400mg | 5.1 | 2.1 | 29.1 | 49.8 | 78.1 |
| Ranolazine 1500mg | 6.5 | 2.7 | 3.3 | 8.8 | 12.6 |
| Verapamil HCl 120 mg | 32.1 | 2.6 | -2.4 | 4.8 | 5.2 |
Evening dose (moxifloxacin+diltiazem) versus afternoon dose (diltiazem alone). (NCT02308748)
Timeframe: 5 weeks
| Intervention | ms (Mean) |
|---|---|
| Moxifloxacin Alone | 29.9 |
| Moxifloxacin + Diltiazem | 31.3 |
After 3rd dose of mexiletine or lidocaine (evening dose) on treatment day when combined with dofetilide to evening dose on dofetilide alone day. (NCT02308748)
Timeframe: 5 weeks
| Intervention | ms (Mean) | |
|---|---|---|
| Placebo corrected change from baseline in QTc | Placebo corrected change from baseline in J-Tpeakc | |
| Dofetilide + Lidocaine | 18 | 3.5 |
| Dofetilide + Mexiletine | 20.4 | 0.8 |
| Dofetilide Alone | 37.9 | 24.0 |
1 trial available for mexiletine and Torsade de Pointes
| Article | Year |
|---|---|
Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Topics: Adult; Biomarkers; Calcium Channel Blockers; Cross-Over Studies; Electrocardiography; Ether-A-Go-Go | 2016 |
Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Topics: Adult; Biomarkers; Calcium Channel Blockers; Cross-Over Studies; Electrocardiography; Ether-A-Go-Go | 2016 |
Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Topics: Adult; Biomarkers; Calcium Channel Blockers; Cross-Over Studies; Electrocardiography; Ether-A-Go-Go | 2016 |
Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Topics: Adult; Biomarkers; Calcium Channel Blockers; Cross-Over Studies; Electrocardiography; Ether-A-Go-Go | 2016 |
12 other studies available for mexiletine and Torsade de Pointes
| Article | Year |
|---|---|
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; | 2011 |
Mexiletine effectively prevented refractory Torsades de Pointes and ventricular fibrillation in a patient with congenital type 2 long QT syndrome.
Topics: Adult; Arrhythmias, Cardiac; DNA-Binding Proteins; Electrocardiography; Female; Humans; Long QT Synd | 2022 |
Congenital long QT syndrome and 2:1 atrioventricular block: an optimistic outcome in the current era.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrioventricular Block; Child; Child, Preschool | 2010 |
Long QT syndrome with nocturnal cardiac events caused by a KCNH2 missense mutation (G604S).
Topics: Child; Electrocardiography; Epinephrine; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; G | 2012 |
Effect of pacing and mexiletine on dispersion of repolarisation and arrhythmias in DeltaKPQ SCN5A (long QT3) mice.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Disease Models, Anim | 2003 |
A case of a short-coupled variant of torsades de Pointes with electrical storm.
Topics: Electrocardiography; Electrophysiologic Techniques, Cardiac; Humans; Male; Mexiletine; Middle Aged; | 2003 |
Images in cardiovascular medicine. Life-threatening neonatal arrhythmia: successful treatment and confirmation of clinically suspected extreme long QT-syndrome-3.
Topics: Bradycardia; Cardiovascular Agents; Electrocardiography; Heart Block; Humans; Infant, Newborn; Infan | 2004 |
Successful parental use of an automated external defibrillator for an infant with long-QT syndrome.
Topics: Anti-Arrhythmia Agents; Combined Modality Therapy; Death, Sudden, Cardiac; Defibrillators; Defibrill | 2006 |
Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Drug Inte | 1995 |
Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Benz(a)Anthracenes; Dogs; Electrocardiography; H | 1997 |
Suppression of erythromycin-induced early afterdepolarizations and torsade de pointes ventricular tachycardia by mexiletine.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Dogs; Electric Stimulatio | 1998 |
Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Disease Models, Animal; Dogs; Dose-R | 1998 |